Vivek Subbiah: Delighted to share my commentary on tissue-agnostic cancer therapies
May 31, 2025, 03:35

Vivek Subbiah: Delighted to share my commentary on tissue-agnostic cancer therapies

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:

“Hot off the press!
Delighted to share with the world my commentary in the journal Nature Communications perfectly timed for American Society of Clinical Oncology (ASCO) annual meeting!
  • “Tissue-agnostic cancer therapies: promise, reality, and the path forward”
  • Diving deep into where we are and where we’re headed with these treatments.
  • What’s your take on molecular vs. anatomical cancer classification? Drop your thoughts below!
Open access free link.”

Vivek Subbiah: Delighted to share my commentary on tissue-agnostic cancer therapies

You can find more posts featuring Vivek Subbiah on OncoDaily.